Long-term effects of BIBN-99, a selective muscarinic M2 receptor antagonist, on improving spatial memory performance in aged cognitively impaired rats

Behavioural Brain Research

Volumn 145, Issue 1-2, 2003, Pages 171-178

  Rowe, W B ^a,b   O'Donnell, J P ^a   Pearson, D ^a,c   Rose, G M ^b   Meaney, M J ^a   Quirion, R ^a  

^a MCGILL UNIVERSITY   (Canada)

^b Memory Pharmaceuticals Corporation   (United States)

^c CMX Research Inc   (Canada)

Author keywords

Aged impaired memory; Aging; Long term memory enhancement; Morris water maze

Indexed keywords

5,11 DIHYDRO 8 CHLORO 11 [[4 [3 [(2,2 METHYL 1 OXOPENTYL)ETHYLAMINO]PROPYL] 1 PIPERIDINYL]ACETYL] 6H PYRIDO[2,3 B][1,4]BENZODIAZEPIN 6 ONE; BIBN 99; CENTRAL NERVOUS SYSTEM AGENTS; MUSCARINIC M2 RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

AGED; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; LEARNING; LONG TERM MEMORY; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT; SPATIAL MEMORY; TASK PERFORMANCE;

EID: 0141869018     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(03)00116-5     Document Type: Article

References (52)

1. Aubert I., Rowe W.B., Meaney M.J., Gauthier S., Quirion R. Cholinergic markers in aged cognitively impaired Long-Evans rats. Neuroscience. 67:1995;277-292.
2. Auld D.S., Kar S., Quirion R. Beta-amyloid peptides as direct cholinergic neuromodulators: a missing link? Trends Neurosci. 21:1998;43-49.
3. Baratti C.M., Opezzo J.W., Kopf S.R. Facilitation of memory storage by the acetylcholine M2 muscarinic receptor antagonist AF-DX 116. Behav. Neural Biol. 60:1993;69-74.
4. Bartus R.T. On neurodegenerative diseases models and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp. Neurol. 163:2000;495-529.
5. Behrends J.C., Ten Bruggencate G. Cholinergic modulation of synaptic inhibition in the guinea pig hippocampus in vitro: excitation of GABAergic interneurons and inhibition of GABA-release. J. Neurophysiol. 69:1993;626-629.
6. Bogdanovic N., Islam A., Nilsson L., Bergstrom L., Winblad B., Adem A. Effects of nucleus basalis lesion on muscarinic receptor subtypes. Exp. Brain Res. 97:1993;225-232.
7. Boluis J.J., Stewart C.A., Forrest E.M. Retrograde amnesia and memory reactivation in rats with ibotenate lesions to the hippocampus or subiculum. Q. J. Exp. Psychol. B. 47:1994;129-150.
8. Carey G.J., Billard W., Binch H.I.I.I., Cohen-Williams M., Crosby G., Grzelak M.et al. SCH 57790, a selective muscarinic M2 receptor antagonist, releases acetylcholine and produces cognitive enhancement in laboratory animals. Eur. J. Pharmacol. 431:2001;189-200.
9. Cavallaro S., D'Agata V., Manikam P., Dufour F., Alkon D.L. Memory-specific temporal profiles of gene expression in the hippocampus. Proc. Natl. Acad. Sci. U.S.A. 99:2002;16279-16284.
10. Doods H.N., Quirion R., Mihm G., Engel W., Rudolf K., Entzeroth M.et al. Therapeutic potential of CNS-active M2 antagonists: novel structures and pharmacology. Life Sci. 52:1993;497-503.
11. Doods H.B., Entzeroth M., Ziegler H., Schiavi G., Engel W., Mihm G.et al. Characterization of BIBN 99: a lipophilic and selective muscarinic M2 receptor antagonist. Eur. J. Pharmacol. 242:1993;23-30.
12. Gage F.H., Kelley P.A.T., Bjorkland A. Regional changes in brain glucose metabolism reflect cognitive impairments in aged rats. J. Neurosci. 4:1984;2856-2865.
13. Gauthier S. Alzheimer's disease: current and future therapeutic perspectives. Prog. Neuropsychopharmacol. Biol. Psychiatry. 25:2001;73-89.
14. Geula C. Abnormalities of neural circuitry in Alzheimer's disease: hippocampus and cortical cholinergic innervation. Neurology. 51:1998;S18-S29.
15. Hajos N., Papp E.C., Acsady L., Levey A.I., Freund T.F. Distinct interneuron types express m2 muscarinic receptor immunoreactivity on their dendrites or axon terminals in the hippocampus. Neuroscience. 82:1998;355-376.
16. Hersi A.I., Rowe W., Gaudreau P., Quirion R. Dopamine D1 receptor ligands modulate cognitive performance and hippocampal acetylcholine release in memory impaired aged rats. Neuroscience. 69:1995;1067-1074.
17. Issa A.M., Rowe W., Gauthier S., Meaney M.J. Hypothalamic-pituitary-adrenal activity in aged, cognitively impaired and cognitively unimpaired rats. J. Neurosci. 10:1990;3247-3254.
18. Lachowicz J.E., Duffy R.A., Ruperto V., Kozlowski J., Zhou G., Clader J.et al. Facilitation of acetylcholine release and improvement in cognition by a selective M2 muscarinic antagonist, SCH 72788. Life Sci. 68:2001;2585-2592.
19. Lapchak P.A., Araujo D.M., Quirion R., Collier B. Binding sites for [3H]AF-DX 116 and effect of AF-DX 116 on endogenous acetylcholine release from rat brain slices. Brain Res. 496:1989;285-294.
20. Levey A.I., Kitt C.A., Simonds W.F., Price D.L., Brann M.R. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J. Neurosci. 11:1991;3218-3226.
21. Levey A.I., Edmunds S.M., Koliatsos V., Wiley R.G., Heilman C.J. Expression of m1-m4 muscarinic acetylcholine receptor proteins in rat hippocampus and regulation by cholinergic innervation. J. Neurosci. 15:1995;4077-4092.
22. Levey A.I., Edmunds S.M., Herrsh S.M., Wiley R.G., Heilman C.J. Light and electron microscopic study of m2 muscarinic acetylcholine receptor in the basal forebrain of the rat. J. Comp. Neurol. 351:1995;339-356.
23. Markowska A.L., Stone W.S., Ingram D.K., Reynolds J., Gold P.E., Conti L.H.et al. Individual differences in aging: behavioral and neurobiological correlates. Neurobiol. Aging. 10:1989;31-43.
24. Markowska A.L., Olton D.S., Givens B. Cholinergic manipulations in the medial septal area: age-related effects on working memory and hippocampal electrophysiology. J. Neurosci. 15:1995;2063-2073.
25. Mash D.C., Flynn D.D., Potter L.T. Loss of muscarine receptors in the cerebral cortex in Alzheimer's Disease and experimental cholinergic denervation. Science. 228:1985;1115-1117.
26. Mumby D.G., Astur R.S., Weisend M.P., Sutherland R. Retrograde amnesia and selective damage to the hippocampal formation: memory for places and object discriminations. Behav. Brain Res. 106:1999;97-107.
27. O'Donnell J, Diaz-Ruiz O, Godbout R, Quirion R. Hippocampal gene expression profiles in young, aged memory-impaired and aged memory-unimpaired Long-Evans rats. Soc Neurosci Abstr 2002; 374.3.
28. Parent A., Rowe W.B., Meaney M.J., Quirion R. Increased production of inositol phosphate and diacylglycerol in aged memory-impaired rats following stimulation of muscarinic, metabotropic-glutamate and endothelin receptors. J. Pharmacol. Exp. Ther. 272:1995;1110-1116.
29. Pike B.R., Hamm R.J. Post-injury administration of BIBN 99, a selective muscarinic M2 receptor antagonist, improves cognitive performance following traumatic brain injury in rats. Brain Res. 686:1995;37-43.
30. Quirion R., Aubert I., Araujo D.M., Hersi A., Gaudreau P. Autoradiographic distribution of putative muscarinic receptor sub-types in mammalian brain. Prog. Brain Res. 98:1993;85-93.
31. Quirion R., Richard J., Wilson A. Muscarinic and nicotinic modulation of cortical acetylcholine release monitored by in vivo microdialysis in freely moving adult rats. Synapse. 17:1994;92-100.
32. Quirion R., Wilson A., Rowe W.B., Aubert I., Richard J., Doods H.et al. Facilitation of acetylcholine release and cognitive performance by an M(2)-muscarinic receptor antagonist in aged memory-impaired. J. Neurosci. 15:1995;1455-1462.
33. Raiteri M., Leardi R., Marchi M. Heterogeneity of presynaptic muscarinic receptors regulating neurotransmitter release in the rat brain. J. Pharm. Exp. Ther. 228:1984;209-214.
34. Regenold W., Araujo D., Quirion R. Direct visualization of brain M2 muscarinic receptors using the selective antagonist [3H]AF-DX116. Eur. J. Pharmacol. 144:1987;417-419.
35. Rowe W.B., Steverman A., Walker M., Sharma S., Barden N., Seckl J.R.et al. Hypothalamic-pituitary-adrenal function in aged cognitively impaired and unimpaired rats: effects of antidepressant drug treatment. Neurobiol. Aging. 18:1997;527-533.
36. Rowe W.B., Spreekmeester E., Meaney M., Quirion R., Rochford J. Reactivity to novelty in cognitively impaired and unimpaired aged rats, and young rats. Neuroscience. 83:1998;669-680.
37. Selkoe D.J. The origins of Alzheimer's disease: a is for amyloid. J. Am. Med. Assoc. 283:2000;1615-1617.
38. Sherman K.A., Kuster J.E., Dean R.L., Bartus R.T., Friedman E. Presynaptic cholinergic mechanisms in brain of aged rats with memory impairments. Neurobiol. Aging. 2:1981;99-104.
39. Smiley J.F., Levey A.I., Mesulam M.M. Infracortical interstitial cells concurrently expressing M2-muscarinic receptors, acetylcholineresterase and nicotinamide adenine dinucleotide phosphate-diaphorase in the human and monkey cerebral cortex. Neuroscience. 84:1998;755-769.
40. Smolders I., Bogaert L., Ebinger G., Michotte Y. Muscarinic modulation of striatal dopamine glutamate and GABA release as measured with in vivo microdialysis. J. Neurochem. 68:1997;1942-1948.
41. Stillman M.J., Shukitt-Hale B., Galli R.L., Levy A., Lieberman H.R. Effects of M2 antagonists on in vivo hippocampus acetylcholine levels. Brain Res. Bull. 41:1996;221-226.
42. Tombaugh G.C., Rowe W.B., Chow A., Michael T., Rose G.M. Theta-frequency synaptic potentiation in CA1 in vitro distinguishes spatially impaired from unimpaired aged F344 rats. J. Neurosci. 22:2002;9932-9940.
43. Vallee M., Mayo W., Le Moal M. Role of pregnenolone dehydroepiandrosterone and their sulfate esters on learning and memory in cognitive aging. Brain Res. Brain Res. Rev. 37:2001;301-312.
44. Van Groen T., Kadish I., Wyss J.M. Old rats remember old tricks; memories of the water maze persist for 12 months. Behav. Brain Res. 136:2002;247-255.
45. Vannucchi M.G., Scali C., Kopf S.R., Pepeu G., Casamenti F. Selective muscarinic antagonists differentially affect in vivo acetylcholine release and memory performances of young and aged rats. Neuroscience. 79:1997;837-846.
46. Vaucher E., Aumont N., Pearson D., Rowe W., Poirier J., Kar S. Amyloid beta peptide levels and its effects on hippocampal acetylcholine release in aged, cognitively impaired and unimpaired rats. J. Chem. Neuroanat. 21:2001;323-329.
47. Vilaro M.T., Wiederhold K.H., Palacios J.M., Mengod G. Muscarinic M2 receptor mRNA expression and receptor binding in cholinergic and non-cholinergic cells in the rat brain: a correlative study using in situ hybridization histochemistry and receptor autoradiography. Neuroscience. 47:1992;367-393.
48. Vincent G.P., Sepinwall J. AF102B, a novel M1 agonist, enhanced spatial learning in C57BL/10 mice with a long duration of action. Brain Res. 597:1992;264-268.
49. Wang Y., Chacklamannil S., Hu Z., Clader J.W., Greenlee W., Billard W.et al. Design and synthesis of piperidinyl analogues as potent and selective M2 muscarinic receptor antagonists. Bioorg. Med. Chem. Lett. 10:2000;2247-2250.
50. Wang Y., Chacklamannil S., Hu Z., McKittrick B.A., Greenlee W., Ruperto V.et al. Sulfide analogues as potent and selective M(2) muscarinic receptor antagonists. Bioorg. Med. Chem. Lett. 12:2002;1087-1091.
51. Wyss J.M., Chambless B.D., Kadish I., Van Groen T. Age-related decline in water maze learning and memory in rats: strain differences. Neurobiol. Aging. 21:2000;671-681.
52. Yau J.L.W., Olsson T., Morris R.G.M., Meaney M.J., Seckl J.R. Glucocorticoids, hippocampal corticosteroid receptor gene expression and antidepressant treatment: relationship with spatial learning in young and aged rats. Neuroscience. 66:1995;571-581.